Therapeutic Asset Ratings

394 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Primary Mediastinal Large B-cell Lymphoma Recurrent	Merck Sharp & Dohme LLC	P2	CCC (53)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Squamous Cell Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
I-Dxd Lung Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (53)
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative Lung Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (53)
Intismeran Squamous Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Lorazepam Lung Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (53)
Medroxyprogesterone acetate Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
mk-1167 Dementia	Merck Sharp & Dohme LLC	P2	CCC (53)
Nemtabrutinib Non-Hodgkin Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Olaparib Advanced Solid Neoplasms	Merck Sharp & Dohme LLC	P2	CCC (53)
Opevesostat Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Pembrolizumab Carcinoid Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Pembrolizumab Parotid Gland Cancer	Merck Sharp & Dohme LLC	P2	CCC (53)
Pembrolizumab Thyroid Gland Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Pembrolizumab Vulvar Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (53)
Pembrolizumab Advanced/Metastatic Solid Tumors	Merck Sharp & Dohme LLC	P1/2	CCC (53)
Zilovertamab Vedotin Burkitt Lymphoma	Merck Sharp & Dohme LLC	P1/2	CCC (53)
Benadryl Breast Neoplasms	Merck Sharp & Dohme LLC	P3	CCC (52)
DEXTROSE Breast Neoplasm	Merck Sharp & Dohme LLC	P3	CCC (52)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Lung Cancer	Merck Sharp & Dohme LLC	P3	CCC (52)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Solid Tumors	Merck Sharp & Dohme LLC	P3	CCC (52)
Lorazepam Breast Neoplasms	Merck Sharp & Dohme LLC	P3	CCC (52)
Lorazepam Non Small Cell Lung Cancer	Merck Sharp & Dohme LLC	P3	CCC (52)
pf-05280586 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Merck Sharp & Dohme LLC	P3	CCC (52)
Rituximab arrx Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Merck Sharp & Dohme LLC	P3	CCC (52)

Showing 226 to 250 of 394 assets

PreviousPage 10 of 16Next